Skip to main content
SpringerLink
Log in

Parkinsonmittel

  • Chapter
Arzneiverordnungs-Report 2016

  • 2088 Accesses

Zusammenfassung

Levodopapräparate sind die führenden Vertreter der Parkinsonmittel. Ihre Verordnungen sind 2015 erneut leicht angestiegen und umfassen 41% des Verordnungsvolumens. An zweiter Stelle folgen die Dopaminrezeptoragonisten mit Konzentration auf Pramipexol. COMT-Hemmer und MAO-B-Hemmer werden in geringeren Umfang verordnet. Die Verordnungen von Anticholinergika und Amantadin stagnieren auf niedrigem Niveau.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ahlskog JE, Uitti RJ (2010): Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 74: 1143–1148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Birkmayer W, Hornykiewicz O (1961): Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien klin Wschr. 78: 787–788

    Google Scholar 

  • Chen JJ, Swope DM (2005): Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878–894

    Article  CAS  PubMed  Google Scholar 

  • Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;(1):CD003468

    Google Scholar 

  • Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004554

    Google Scholar 

  • Deutsche Gesellschaft für Neurologie (2012): Parkinson-Syndrome—Diagnostik und Therapie. Internet: http://www.dgn.org/leitlinien-online-2012/inhalte-nachkapitel/2346-ll-09-2012-parkinson-syndrome-diagnostikund-therapie.html

  • European Medicines Agency (EMA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: http://www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf

  • Fahn S and the Parkinson Study Group (2005): Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252 (Suppl 4): IV37–IV42

    Google Scholar 

  • Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators (2007): Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398–2404

    Google Scholar 

  • Huntington Study Group (2006): Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366–372

    Article  Google Scholar 

  • Kalia LV, Lang AE (2015): Parkinson’s disease. Lancet 386: 896–912

    Article  CAS  PubMed  Google Scholar 

  • Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;(2):CD003735

    Google Scholar 

  • Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 311: 1602–1607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lees AJ, Hardy J, Revesz T (2009): Parkinson’s disease. Lancet 373: 2055–2066

    Article  CAS  PubMed  Google Scholar 

  • Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001): Tenyear follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687–1694

    Article  CAS  PubMed  Google Scholar 

  • Müller-Vahl KR (2007): Die Benzamide Tiaprid, Sulpirid und Amisulprid in der Therapie des Tourette-Syndroms. Eine Standortbestimmung. Nervenarzt 78: 264–271

    Article  PubMed  Google Scholar 

  • Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators (2009): A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361: 1268–1278

    Article  CAS  PubMed  Google Scholar 

  • Ossig C, Reichmann H (2013): Treatment of Parkinson’s disease in the advanced stage. J Neural Transm 120: 523–529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, Nyholm D, Sydow O, Wainwright M, Widner H, Johansson A (2012): Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126: e29–33

    Article  PubMed  Google Scholar 

  • Parkinson Study Group (2004): A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561–566

    Article  Google Scholar 

  • Parkinson Study Group (2005): A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241–248

    Article  Google Scholar 

  • Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators (2007): Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513–520

    Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa.N Engl J Med 342: 1484–1491

    Google Scholar 

  • Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group (2005): Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365: 947–954

    Article  CAS  PubMed  Google Scholar 

  • Rascol O, Lozano A, Stern M, Poewe W (2011): Milestones in Parkinson’s disease therapeutics. Mov Disord 26: 1072–1082

    Article  PubMed  Google Scholar 

  • Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158

    Article  CAS  PubMed  Google Scholar 

  • Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson’s disease. Neurology 50 (Suppl 6): S18–S22; discussion S44–S48

    Article  CAS  PubMed  Google Scholar 

  • Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010): Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68: 18–27

    Article  CAS  PubMed  Google Scholar 

  • The Parkinson Study Group (2004): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Neuenheimer Feld 366, 69120, Heidelberg

    Prof. em. Dr. med. Ulrich Schwabe

Authors
  1. Prof. em. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2016). Parkinsonmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50351-5_40

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50350-8

  • Online ISBN: 978-3-662-50351-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation